Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shionogi’s H1 Sales Wane 2.3% as Crestor Royalties Almost Disappear
November 2, 2021
- Shionogi Wants to Pick Global Partner for Oral COVID-19 Drug by Year-End: President
November 2, 2021
- Eisai’s Medium Molecule E7386 Hits POC, Keytruda Combo Study Now Underway
November 2, 2021
- Daiichi Sankyo Launches Oncolytic Virus Delytact in Japan
November 2, 2021
- Astellas’ Half-Year Revenue Up Nearly 6% on Bullish Xtandi
November 1, 2021
- Otsuka Files HIF-PH Inhibitor Vadadustat in Europe
November 1, 2021
- Hypertension OK Now in Hand, Novartis Expanding Entresto Pitch to GPs with Superior Efficacy over ARBs
November 1, 2021
- Senju Gearing Up to Grow Lucentis Biosimilar into Its Mainstay Product
November 1, 2021
- Daiichi Sankyo’s 1st Half Operating Profit Jumps 44.9% Thanks to Lixiana, Enhertu
November 1, 2021
- Japan Pharma Market Expected to Log -0.8% to +0.2% Growth through FY2026: IQVIA
October 29, 2021
- Takeda’s H1 Sales Log Two-Digit Growth Driven by Global Brands, FDA Wraps Up Plant Re-Inspection
October 29, 2021
- Takeda to Snap Up UK Cell Therapy Partner GammaDelta
October 29, 2021
- Ono Files Onoact for Pediatric Tachyarrhythmia
October 29, 2021
- Sumitomo Dainippon to Speed Up Development of CNS Blockbuster Hopeful through Otsuka Alliance
October 28, 2021
- Otsuka Collaboration “More Positive” than Solo Even If Profits Shared: Sumitomo Dainippon Chief
October 28, 2021
- Sumitomo Dainippon’s H1 Sales Surge 12.3% on Otsuka Deal
October 28, 2021
- Chugai/TWOCELLS Complete PIII Enrollment for Knee Chondrogenesis Cell Medicine
October 28, 2021
- CNS Alliance with Otsuka Expected to be Long-term: Sumitomo Dainippon Senior Executive
October 28, 2021
- AbbVie Seeks Ulcerous Colitis Indication for Rinvoq in Japan
October 28, 2021
- Nobelpharma Plans Launch of 3 Products in US, China, Europe: R&D Head
October 27, 2021
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…